TrialBortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
Trial details
- Registry ID
- NCT03110562
- Phase
- Phase 3
Drug research
Bortezomib
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as Velcade; Velcade®
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple MyelomaNCT03110562 | KPTI | Phase 3 | Completed | 2020-02-18Actual |
| A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.NCT04414475 | KPTI | Phase 2 | Recruiting | 2028-01Estimated |
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Trial details
- Registry ID
- NCT04414475
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |